Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells

Pharmaceutical Research

Volumn 31, Issue 8, 2014, Pages 1978-1988

  Tran, Tuan Hiep ^a   Ramasamy, Thiruganesh ^a   Truong, Duy Hieu ^a   Shin, Beom Soo ^b   Choi, Han Gon ^c   Yong, Chul Soon ^a   Kim, Jong Oh ^a  

^a Yeungnam University   (South Korea)

^b Catholic University of Daegu   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

Bioavailability; Drug resistance; Pharmacokinetics; Solid lipid nanoparticle; Vorinostat

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG CARRIER; HYDROXAMIC ACID; LIPID; NANOPARTICLE; VORINOSTAT;

ANIMAL; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; HUMAN; MALE; MCF 7 CELL LINE; METABOLISM; MULTIDRUG RESISTANCE; PHYSIOLOGY; PROCEDURES; RAT; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYDROXAMIC ACIDS; LIPIDS; MALE; MCF-7 CELLS; NANOPARTICLES; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 84894051072     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1300-z     Document Type: Article

References (51)

1. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007;25:84-90.
2. Cai YY, Yap CW, Wang Z, Ho PC, Chan SY, Ng KY, et al. Solubilization of vorinostat by cyclodextrins. J Clin Pharm Ther. 2010;35:521-6.
3. Choo QY, Ho PC, Lin HS. Histone deacetylase inhibitors: new hope for rheumatoid arthritis? Curr Pharm Des. 2008;14:803-20.
4. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769-84.
5. Mohamed EA, Zhao Y, Meshali MM, Remsberg CM, Borg TM, Foda AM, et al. Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(DL-Lactic Acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine. J Pharm Sci. 2012;101:3787-98.
6. Kavanaugh SA, White LA, Kolesar JM. Vorinostat: a novel therapy for the treatment of cutaneous T-cell lymphoma. Am J Health Syst Pharm. 2010;67:793-7.
7. Kelly WK, O'Connor OA, Krug ML, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23:3923-31.
8. Iwamoto M, Friedman EJ, Sandhu P, Agrawal NG, Rubin EH, Wagner JA. Cancer Chemother Pharmacol. 2013;72:493-508.
9. Richard J. Challenges and opportunities in the delivery of cancer therapeutics. Ther Deliv. 2011;2:107-21.
10. Strobl JS, Nikkhah M, Agah M. Actions of the anti-cancer drug suberoylanilide hydroxamic acid (SAHA) on human breast cancer cytoarchitecture in silicon microstructures. Biomaterials. 2010;31:7043-50.
11. Zhang P, Ling G, Pan X, Sun J, Zhang T, Pu X, et al. Novel nanostructured lipid-dextran sulfate hybrid carriers overcome tumor multidrug resistance of mitoxantrone hydrochloride. Nanomedicine. 2012;8:185-93.
12. Liu J, Gong T, Wang C, Zhong Z, Zhang Z. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Int J Pharm. 2007;340:153-62.
13. Das S, Choudhary A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech. 2011;12:62-76.
14. Suresh G, Manjunath K, Venkateswarlu V, Satyanarayana V. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech. 2007;8:E162-70.
15. Xu Z, Chen L, Gu W, Gao Y, Lin L, Zhang Z, et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials. 2009;30:226-32.
16. Ramasamy TG, Haidar ZS. Formulation, characterization and cytocompatibility evaluation of novel core-shell solid lipid nanoparticles for the controlled and tunable delivery of a model protein. J Bionanosci. 2011;5:143-54.
17. Carneiro G, Silva EL, Pacheco LA, de Souza-Fagundes EM, Corrêa NC, de Goes AM, et al. Formation of ion pairing as an alternative to improve encapsulation and anticancer activity of all-trans retinoic acid loaded in solid lipid nanoparticles. Int J Nanomedicine. 2012;7:6011-20.
18. Mussi SV, Silva RC, Oliveira MC, Lucci CM, Azevedo RB, Ferreira LA. New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Eur J Pharm Sci. 2013;48:282-90.
19. Pradhan R, Poudel BK, Ramasamy TG, Choi HG, Yong CS, Kim JO. Docetaxel-loaded PLGA nanoparticles: formulation, physicochemical characterization and cytotoxicity studies. J Nanosci Nanotechnol. 2013;13:5948-56.
20. Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs. 2005;14:1497-511.
21. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A. 2000;97:10014-9.
22. Huang JM, Sheard MA, Ji L, Sposto R, Keshelava N. Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53. Mol Cancer Ther. 2010;9:3289-301.
23. Ozaki K, Kishikawa F, Tanaka M, Sakamoto T, Tanimura S, Kohno M. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci. 2008;99:376-84.
24. Konsoula R, Jung M. In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors. Int J Pharm. 2008;361:19-25.
25. Zhu R, Cheng KW, Mackenzie G, Huang L, Sun Y, Xie G, et al. Phospho-Sulindac (OXT-328) Inhibits the Growth of Human Lung Cancer Xenografts in Mice: Enhanced Efficacy and Mitochondria Targeting by its Formulation in Solid Lipid Nanoparticles. Pharm Res. 2012;29:3090-101.
26. Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR, et al. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res. 2009;69:3918-26.
27. Li S, Su Z, Sun M, Xiao Y, Cao F, Huang A, et al. Anarginine derivative contained nanostructure lipid carriers with pH-sensitive membranolytic capability for lysosomolytic anti-cancer drug delivery. Int J Pharm. 2012;436:248-57.
28. Chen CC, Tsai TH, Huang ZR, Fang JY. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm. 2010;74:474-82.
29. Kheradmandnia S, Vasheghani-Farahani E, Nosrati M, Atyabi F. Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax. Nanomedicine. 2010;6:753-9.
30. Lim SJ, Kim CK. Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int J Pharm. 2002;243:135-46.
31. Wissing SA, Müller RH. Solid lipid nanoparticles (SLN)-a novel carrier for UV blockers. Pharmazie. 2001;56:783-6.
32. Venishetty VK, Komuravelli R, Kuncha M, Sistla R, Diwan PV. Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles. Nanomedicine. 2013;9:111-21.
33. Yuan H, Miao J, Du YZ, You J, Hu FQ, Zeng S. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm. 2008;348:137-45.
34. Silva AC, Kumar A, Wild W, Ferreira D, Santos D, Forbes B. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles. Int J Pharm. 2012;436:798-805.
35. Kim JO, Ramasamy T, Yong CS, Nukolova N, Bronich TK, Kabanov AV. Cross-linked polymeric micelles based on block ionomer complexes. Mendeleev Comm. 2013;23:179-86.
36. Zhang X, Liu J, Qiao H, Liu H, Ni J, Zhang W, et al. Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol. 2010;197:120-8.
37. Rawat K, Jain A, Singh S. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation. J Pharm Sci. 2011;100:2366-78.
38. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S131-55.
39. Bosea S, Duc Y, Takhistovc P, Michniak-Kohn B. Formulation optimization and topical delivery of quercetin from solid lipid based nano systems. Int J Pharm. 2013;441:56-66.
40. Jaina A, Agarwala A, Majumderb S, Lariyaa N, Khayaa A, Agrawalc H, et al. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release. 2010;148:359-67.
41. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48-58.
42. Wang S, Chen T, Chen R, Hu Y, Chen M, Wang Y. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies. Int J Pharm. 2012;430:238-46.
43. Di Bernardo G, Alessio N, Dell'Aversana C, Casale F, Teti D, Cipollaro M. Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells. J Cell Physiol. 2010;225:537-44.
44. Tiwari R, Pathak K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm. 2011;415:232-43.
45. Jacobs C, Kayser O, Muller RH. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm. 2000;196:161-4.
46. Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res. 1999;16:751-7.
47. Luo YF, Chen DW, Ren LX, Zhao XL, Qin J. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release. 2006;114:53-9.
48. Sandhu P, Andrews PA, Baker MP, Koeplinger KA, Soli ED, Miller T, et al. Disposition of vorinostat, a novel histone deacetylase inhibitor and anticancer agent, in preclinical species. Drug Metab Lett. 2007;1:153-61.
49. Kim JO, Oberoi H, Desale SH, Kabanov AV, Bronich TK. Polypeptide nanogels with hydrophobic moieties in the cross-linked ionic cores: synthesis, characterization and implications for anticancer drug delivery. J Drug Target. 2013;21:981-93.
50. Tran TH, Ramasamy T, Cho HJ, Kim YI, Poudel BK, Choi HG, et al. Formulation and optimization of raloxifene-loaded solid lipid nanoparticles to enhance oral bioavailability. J Nanosci Nanotechnol. 2013;Accepted.
51. Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomed. 2007;2:289-300.